ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: In vitro characterization and effects in animal models of Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 1, 1996, Pages 150-160

  Shiosaki, Kazumi ^a   Jenner, Peter ^a,b   Asin, Karen E ^a   Britton, Donald R ^a   Lin, Chun Wel ^a   Michaelides, Michael ^a   Smith, Lance ^a,b   Bianchi, Bruce ^a   Didomenico, Stanley ^a   Hodges, Lisa ^a   Hong, Yufeng ^a,c   Mahan, Laura ^a   Mikusa, Joe ^a   Miller, Thomas ^a   Nikkel, Arthur ^a   Stashko, Michael ^a   Witte, David ^a   Williams, Michael ^a  

^a ABBOTT LABORATORIES   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Alanex Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BUTANEDIONE; 4,5,5A,6,7,11B HEXAHYDRO 9,10 DIHYDROXY 2 PROPYL 3 THIA 5 AZACYCLOPENT 1 ENA[C]PHENANTHRENE; ADROGOLIDE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; PRODRUG; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; IN VITRO STUDY; LOCOMOTION; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CALLITHRIX; CHO CELLS; CORPUS STRIATUM; CRICETINAE; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FISHES; HUMANS; KINETICS; MALE; MICE; PARKINSON DISEASE, SECONDARY; PRODRUGS; PYRIDINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 15844379678     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. ACQUAS, E., DAY, J. AND FIBIGER, H.: The potent and selective dopamine D1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat. Eur. J. Pharmacol. 260: 85-87, 1994.
2. AGID, Y.: Parkinson's disease: Pathophysiology. Lancet 337: 1321-1324, 1991.
3. ARNSTEN, A., CAI, J., MURPHY, B. AND GOLDMAN-RAKIC, P.: Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116: 143-151, 1994.
4. ASIN, K. E. AND WIRTSHAFTER, D.: Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression. Eur. J. Pharmacol. 235: 167-168, 1993.
5. BLANCHET, P., BEDARD, P. J., BRITTON, D. R. AND KEBABIAN, J. W : Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J. Pharmacol. Exp. Ther. 267: 275-279, 1993.
6. 2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp Ther. 272: 854-859, 1995.
7. BOYCE, S., RUPNIAK, N M. J., STEVENTON, M. J. AND IVERSEN, S. D.: Characterization of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 102: 21-27, 1990
8. BRAUN, A., FABBRINI, G., MOURADIAN, M., SERRATI, C., BARONE, P. AND CHASE, T.: Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J. Neural Transm. 68: 41-50, 1987.
9. CALNE, D.: Early Idiopathic Parkinsonism: Initiation and optimization of treatment. Clin. Neuropharmacol. 17: S14-S18, 1994.
10. CALNE, D.: Is idiopathic Parkinsonism the consequence of an event or a process? Neurology 44: 5-10, 1994.
11. FACTOR, S. AND BROWN, D.: Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov. Disord. 7: 125-131, 1992.
12. FREMEAU, R., JR., DUNCAN, G., FORNARETTO, M.-G., DEARRY, A., GINGRICH, J., BREESE, G. AND CARON, M.: Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Neurobiology 88: 3772-3776, 1991.
13. GINGRICH, J. A. AND CARON, M. G.: Recent advances in the molecular biology of dopamine receptors. Ann. Rev. Neurosci. 16: 299-321, 1993.
14. GRONDIN, R., BLANCHET, P. J., BEDARD, P. J., BRITTON, D. R., SHIOSAKI, K. AND KEBABIAN, J. W.: Dramatic desensitization of the behavioral response to a long-acting D1 but not D2 agonist in MPTP monkeys (Abstract). Soc. Neurosci. 20: 1645, 1994.
15. HEIKKILA, R E , SONSALLA, P. K. AND DUVOISIN, R.: Biochemical models of Parkinson's disease. In Neuromethods: Drugs as Tools in Neurotransmitter Research, ed. by A. A. Boulton, G. B. Baker and A. V. Juorio, vol 12, pp. 351-384, Humana Press, Clinfton, NY, 1989.
16. IRWIN, I.: The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A key to Parkinson's disease? Pharmaceut. Res. 3: 7-11, 1986.
17. KEBABIAN, J. W., BRITTON, D. R., DENINNO, M. P., PERNER, R., SMITH, L., JENNER, P , SCHOENLEBER, R. AND WILLIAMS, M.: A-77636: A potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur. J. Pharmacol. 229: 203-209, 1992
18. KEBABIAN, J. W., PETZOLD, G. L. AND GREENGARD, P.: Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor." Proc. Natl. Acad. Sci. U.S.A. 69: 2145-2149, 1972.
19. KERKMAN, D., ACKERMAN, M., ARTMAN, L., MACKENZIE, R., JOHNSON, M., BEDNARZ, L., MONTANA, W., ASIN, K., STAMPFLI, H., AND KEBABIAN, J.: A-69025. A non-benzazepine antagonist with selectivity for the dopamine D-1 receptor. Eur. J. Pharmacol. 166: 481-491, 1989.
20. KORCZYN, A. D.: Parkinson's disease. In Psychopharmacology: The Fourth Generation of Progress, ed by F. E. Bloom and D J. Kupfer, pp. 1479-1484, Raven Press, New York, NY, 1995.
21. LIN, C., MILLER, T , WITTE, D., BIANCHI, B., STASHKO, M., MANELLI, A. AND FRAIL, D.: Characterization of Cloned Human Dopamine D1 Receptor-Mediated Calcium Release in 293 Cells. Mol. Pharmacol. 47: 131-139, 1995.
22. LOSCHMANN, P., SMITH, L., LANGE, K., JAEHNIG, P., JENNER, P. AND MARSDEN, C.: Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets. Psychopharmacology 105: 303-309, 1991.
23. MADRAS, B. K., ELMALEH, D., MELTZER, P., LEE-PARRITZ, D. E., HANTRAYE, P., ISACSON, O., BROWNELL, G. L. AND BROWNELL, A. L.: Parkinsonian signs in MPTP-treated monkeys are alleviated by the high efficacy D1 dopamine receptor agonist SKF-81297 (Abstract). Soc Neurosci. 18: 1992.
24. MARSDEN, C.: Parkinson's disease. J. Neurol. Neurosurg. Psych. 57: 672-681, 1994a.
25. MARSDEN, C.: Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 17: S32-S44, 1994b.
26. MICHAELIDES, M. R., HONG, Y., DIDOMENICO, S. D., JR., ASIN, K E., BRITTON, D. R., LIN, C. W., WILLIAMS, M. AND SHIOSAKI, K.: (5aR,11bS)-4,5,5a,6,7,11b-Hexahydro-2-propyl-3-thia-5-aza-cyclopent-1-ena[c] phenanthrene-9,10-diol (A-86929): A potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration, and characterization of its diacetyl prodrug (ABT-431). J. Med. Chem. 38: 3445-3447, 1995.
27. NOMOTO, M., JENNER, P. AND MARSDEN, C.: The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci. Lett. 57: 37-41, 1985
28. OBESO, J., GRANDAS, F., HERRERO, M. AND HOROWSKI, R : The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur. J. Neurosci. 6: 889-897, 1994.
29. SAWAGUCHI, T. AND GOLDMAN-RAKIC, P.: D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science (Wash. DC) 251: 947-950, 1991.
30. SCHNEIDER, J., SUN, Z.-Q AND ROELTGEN, D.: Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res. 663: 140-144, 1994.
31. SIBLEY, D. AND MONSMA, F.: Molecular biology of dopamine receptors. Trends Pharmacol. Sci 13: 61-69, 1992.
32. STACY, M.: Current approaches in the treatment of Parkinson's disease. Annu. Rev. Med. 43: 431-440, 1993.
33. STANDAERT, D.: Update on the management of Parkinson's disease Contemp. Clin. Neurol 77: 169-183, 1993.
34. SUNAHARA, R. K., GUAN, H.-C., O'DOWD, B. F., SEEMAN, P., LAURIER, L. G., NG, G., GEORGE, S. R., TORCHIA, J., VAN TOL, H. H. M. AND NIZIK, H. B.: Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature (Lond.) 350: 614-619, 1991.
35. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacological Calculations with Computer Programs. Springer-Verlag, New York, NY, 1987.
36. TANG, L., TODD, R. D., HELLER, A AND O'MALLEY, K. L.: Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol. Exp. Ther. 268: 495-502, 1994
37. TAYLOR, J., LAWRENCE, M., REDMOND, D., ELSWORTH, J., ROTH, R , NICHOLS, D. AND MAILMAN, R.: Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced Parkinsonism in the African green monkey (Abstract). Soc. Neurosci. 17: 1075, 1991.
38. TEMLETT, J., CHONG, P., OERTEL, W., JENNER, P. AND MARSDEN, C.: The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur. J. Pharmacol. 156: 197-206, 1988.
39. TEMLETT, J., QUINN, N., JENNER, P. G. J., MARSDEN, C., POURCHER, E., BONNET, A., AGID, Y., MARKSTEIN, R. AND LATASTE, X.: Antiparkinsonian activity of CY-208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov. Disord. 4: 261-265, 1989.
40. TIBERI, M. AND CARON, M. G.: High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J. Biol. Chem. 269: 27925-27931, 1994.
41. WATER, C. M., HUNT, S. P., JENNER, P. AND MARSDEN, C. D.: An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience 23: 1025-1039, 1987.